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Abstract 
Eukaryotic DNA replication starts with the assembly of a pre-replication complex (pre-RC) at 
replication origins. We have previously demonstrated that Metaphase Chromosome Protein 
1 (MCP1) is involved in the early events of DNA replication. Here we show that MCP1 as-
sociates with proteins that are required for the establishment of the pre-replication complex. 
Reciprocal immunoprecipitation analysis showed that MCP1 interacted with Cdc6, ORC2, 
ORC4, MCM2, MCM3 and MCM7, with Cdc45 and PCNA. Immunofluorescence studies 
demonstrated the co-localization of MCP1 with some of those proteins. Moreover, bio-
chemical studies utilizing chromatin-immunoprecipitation (ChIP) revealed that MCP1 pref-
erentially binds replication initiation sites in human cells. Interestingly, although members of 
the  pre-RC  are  known  to  interact  with  some  hallmarks  of  heterochromatin,  our 
co-immunoprecipitation and immunofluorescence analyses showed that MCP1 did not in-
teract and did not co-localize with heterochromatic proteins including HP1 and MetH3K9. 
These observations suggest that MCP1 is associated with replication factors required for the 
initiation of DNA replication and binds to the initiation sites in loci that replicate early in 
S-phase. In addition, immunological assays revealed the association of MCP1 forms with 
histone H1 variants and mass spectrometry analysis confirmed that MCP1 peptides share 
common sequences with H1.2 and H1.5 subtypes. 
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INTRODUCTION 
Eukaryotic replication starts with the assembly 
and  the  formation  of  the  pre-replication  complex 
(pre-RC) at replication origins during late mitosis or 
early G1 phase. Initiation of DNA replication requires 
the binding of the origin recognition complex (ORC) 
to particular DNA sequences termed replication ori-
gins  [1-3].  ORC  serves  as  a  loading  dock  for  the 
binding of Cdc6 and Cdt1 that then recruit MCM2-7 
proteins to form the pre-replication complex that is 
activated upon binding of MCM10 [3-8]. Phosphory-
lation by CDKs and Cdc7-Dbf4 promote the attach-
ment  of  Cdc45  that  is  required  to  load  DNA  poly-
merase-alpha as well as for chromosome unwinding 
[9-11]. RPA recruits primase to the origins and stabi-Int. J. Biol. Sci. 2011, 7 
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lizes unwound DNA [3, 10]. Proliferating Cell Nuclear 
Antigen (PCNA) is needed to enhance the processiv-
ity of DNA polymerases [4, 12-14]. The initiation of 
DNA replication is also regulated by structural tran-
sitions in chromosome organization that require the 
interaction of histone H1 and its variants with nucle-
osomes [15, 16] via high-mobility group (HMG) pro-
teins that compete with the binding of H1 to chroma-
tin [17] and through posttranslational modifications of 
histones [7, 16, 18-20].  
Metaphase  Chromosome  Protein  1  (MCP1),  an 
evolutionarily conserved protein with two forms, 33 
kDa and 31 kDa [21], was first identified as the target 
of an antibody present in serum from a mouse with 
systemic lupus erythematosus (SLE). SLE is an auto-
immune  disease,  in  human  and  animals,  character-
ized  by  the  production  of  autoantibodies  that  react 
with a wide number of cellular antigens, mostly lo-
calized within the nucleus [21-23]. MCP1 exhibits a 
granular nuclear localization in interphase cells, alt-
hough it is excluded from the nucleolus, and during 
mitosis  MCP1  is  tightly  bound  to  condensed  chro-
mosomes [24]. Functional studies showed that MCP1 
is required for DNA replication, in particular at G1/S 
transition and during early S-phase, since microinjec-
tion  of the specific antibody against MCP1 into the 
nucleus of human HeLa and rat kangaroo Ptk2 cells 
prevents  S-phase  progression  [25],  suggesting  that 
MCP1 is specifically required for the initiation of rep-
lication events.  
In  order  to  identify  proteins  that  interact  with 
MCP1 in the early events of DNA replication we de-
termined whether MCP1 binding to replication factors 
varied  at  different  stages  of  interphase,  whether  it 
co-localized with replication components and wheth-
er it preferentially binds replication origins.  
MATERIAL AND METHODS  
Cell lines 
Human HeLa (CCL-93021013 cells from ECACC, 
a human cervix epithelial  carcinoma cell line; chro-
mosome  number  2n=46)  and  MO59K  cells 
(ATCC-CRL2365, a human brain, glial cell, glioblas-
toma, glioma; modal chromosome number = 75 with a 
range of 65 to 79) were grown as monolayers in Glu-
taMax Dulbecco’s modified Eagle medium (DMEM) 
supplemented with antibiotics (100 i.u./ml penicillin, 
100 g/ml streptomycin, and 25 g/ml amphotericin 
B), and 10% fetal calf serum (FCS), at 37ºC under 5% 
CO2. Human K562 (ECACC-89121407 cells), a human 
Caucasian  chronic  myelogenous  leukaemia  cell  line 
(chromosome  number  2n=46)  was  grown  in  RPMI 
supplemented with antibiotics and 10% FCS, at 37ºC 
under 5% CO2. Tissue culture reagents were supplied 
by Gibco, BRL (Gaithersburg, MD, USA). 
Cell synchronization and drug treatments  
HeLa and MO59K cells were plated at 1x106/ml 
and were synchronized G1/S with 1 g/ml aphidico-
lin  (APH),  2.5  mM  hydroxyurea  (HU)  and  2.5  mM 
thymidine (Thym) for 18 hours or by double thymi-
dine  block  (DTB).  Releasing  experiments  were  per-
formed  after  washing  the  drugs,  by  incubation  in 
culture  media  without  drugs,  for  8  hours.  In  both, 
synchronization and releasing experiments, cells were 
washed,  pulse  labeled  with  50  M  of 
5-bromo-2’-deoxiuridine (BrdU; Sigma Chemical Co) 
for 20 minutes, fixed in 70% ethanol overnight at 4ºC 
or  with  3.7%  paraformaldehyde  (PFA)  in  HPEM 
buffer (30 mM Hepes, 65 mM Pipes, 10 mM EGTA, 2 
mM MgCl2, pH=6.9, containing 0.5% Triton X-100) at 
room temperature (RT) for 10 minutes [25]. Results 
represent  three  assays  performed  in  duplicated  for 
each cell line. 
Centrifugal elutriation and cell cycle analysis  
Human K562 cells at different phases of cell cycle 
were  enriched  by  centrifugal  elutriation  (Beckman 
Coulter, Avanti J-20 centrifuge and JE-5.0 rotor with a 
40-ml chamber). Rotor speed was maintained at 2,000 
rpm at 4ºC, and the medium flow was controlled by a 
Cole-Parmer  Masterflex  pump.  Cells  were  equili-
brated in the chamber for 10 minutes with a constant 
flow  of  20  ml/min  for  efficient  separation  and  the 
removal of cellular debris. Fractions (50 ml) were col-
lected at increasing flow rates ranging from 24 to 50 
ml/min  and  samples  of  each  fraction  analyzed  by 
FACS (FACSCalibur flow cytometer, Becton Dickin-
son, Mountain View, CA) with excitation of 488 nm to 
establish distribution of cells through the cell cycle. 
Cell numbers were normalized prior to preparation of 
nuclear extracts. HeLa cells labeled with 50 M BrdU, 
were  trypsinized,  washed  twice  with  PBS  (phos-
phate-buffered saline) and fixed with ice-cold ethanol 
70%  overnight.  DNA  from  1x106  cells/ml  was  de-
naturated in 1.5 N HCl for 30 minutes at room tem-
perature,  and  BrdU  was  labeled  with  mouse  an-
ti-BrdU-FITC (0.5 g/ml) antibody (Becton Dickinson 
& Co). Cells were resuspended in DNA staining solu-
tion  [0.5  mg/ml  RNase  (Quiagen,  USA),  50  g/ml 
propidium iodide (Sigma Chemical Co) in PBS]. DNA 
content of the cells was analyzed by FACS. Data were 
acquired in a listmode data file, gated to 25,000 events 
in cell cycle, using the CellQuest Pro software, version 
4.0.2 (Becton Dickinson) included in the system. Cell 
cycle was analyzed using the CellQuest Pro software 
program. Results represent three assays performed in Int. J. Biol. Sci. 2011, 7 
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duplicated. 
Immunoprecipitation and western blotting  
HeLa,  MO59K,  and  K562  nuclei  preparations 
were prepared as described [26], and chromatin di-
gestion was performed treating nuclear extracts with 
micrococcal nuclease  40g/ml,  for  30  minutes  on  ice. 
K562  histone  protein  preparations  were  performed 
according  to  the  method  previously  described  [27]. 
Total HeLa cell extracts were prepared as described 
[21].  Immunoprecipitation  experiments  were  per-
formed according to published methods [28]. Briefly, 
isolated  nuclei  were  resuspended  in  1  ml  of  NET 
buffer (50 mM Tris-HCl pH=7.5, 150 mM NaCl, 1 mM 
EDTA, 0.1% Nonidet P-40, 0.25% gelatin, 0.5% sodium 
deoxycholate)  containing  0.1  mM  PMSF,  5  mM 
-glycerophosphate  and  1%  of  a  standard  protease 
inhibitor cocktail (Sigma Chemical Co), and incubated 
with pre-immune sera and protein A Sepharose beads 
(Santa  Cruz  Biotechnology,  Inc)  30  minutes  at  4ºC. 
Cleared  lysate  was  incubate  (2  hours  at  4ºC)  sepa-
rately with the antibody of interest or with immuno-
globulin G. Antibody complexes were precipitated (1 
hour at 4ºC) with protein A or protein G Sepharose 
beads  (Santa  Cruz  Biotechnology,  Inc).  Precipitates 
were  extensively  washed  with  NET  buffer  and  re-
suspended in SDS-sample buffer. After electrophore-
sis, western blotting was performed using polyvinyl-
idene  difluoride  (PVDF)  membrane  (Immobi-
lon-P-Milipore, Bedford, MA) as described previously 
[28]. Immune signals were detected using the Super-
Signal West Pico Chemiluminescent Substrate (Pierce, 
USA). 
Immunofluorescence  
Indirect  immunofluorescence  was  performed 
according  to  the  methods  previously  described  [24, 
25]. Cells were fixed in 3.7% PFA in HPEM buffer at 
RT  for  10  minutes.  For  PCNA  detection,  cells  were 
treated  with  hypotonic  lyses  solution  (10  mM 
Tris-HCl pH=7.4, 2.5 mM MgCl2, 0.5% Nonidet P-40, 1 
mM PMSF) for 8 minutes and fixed with 4% PFA for 
10  minutes  followed  by  ice-cold  methanol  for  15 
minutes. DNA visualization was performed using 0.5 
g/ml  4’,6-diamidino-2-phenylindole  (DAPI)  in 
mounting media (Biomeda Corp., CA). All prepara-
tions were observed in an Olympus IX 70 microscope 
using 63x and 100x objectives. Images were processed 
with Adobe Photoshop 7.0 (Adobe) software. 
Chromatin immunoprecipitation (ChIP) 
Exponential  growing  human  K562  cells  at  dif-
ferent phases of the cell cycle were obtained by cen-
trifugal  elutriation  (Beckman  Coulter,  Avanti  J-20 
centrifuge). Analysis of asynchronous cells was per-
formed  in  a  FACSCalibur  flow  cytometer  (Becton 
Dickinson,  Mountain  View,  CA).  Cells  were  fixed 
with  1%  formaldehyde  and  quenching  of  cross-link 
was performed with glycine. Cells were sonicated six 
times with a 2-mm tip of a sonicator (Sonics & Mate-
rial, Inc.) at the maximum setting for 20 seconds, at 1 
minute intervals. After centrifugation at 14,000 rpm 
for 20 minutes, the cleared supernatant was incubated 
in 1X RIPA buffer [10 mM Tris pH=8.0, 150 mM NaCl, 
1% Triton X-100, 0.1% SDS, 1 mM EDTA, 1 mM PMSF 
an 1% of a standard protease inhibitor cocktail (Sigma 
Chemical Co)]. To reduce nonspecific binding to pro-
tein  A,  chromatin  was  pre-cleared  with  10  l  plus 
protein A agarose (Santa Cruz Biotechnology, Inc) for 
1 hour at 4ºC with rotation. The pre-cleared chromatin 
(0.5 ml) was incubated in the presence and absence of 
10 g of anti-MCP1 antibody (mAb402) and was ro-
tated  at  4ºC  for  12-14  hours.  Protein  A  beads  were 
added to the ChIP mixture and incubated another 4-6 
hours. The beads were washed with 1X RIPA buffer, 
three times with 1X RIPA plus 0.5 M NaCl, twice with 
Tris-LiCl buffer (10 mM Tris-HCl pH=8.0, 0.25 mM 
LiCl, 1% NP-40, 1% deoxycholate and 1mM EDTA), 
and twice with TE (pH=8). A volume of 0.5 ml elution 
buffer (10 mM Tris-HCl pH=8.0, 200 mM NaCl, 0.5% 
SDS and 1 mM EDTA), was then added to protein A 
beads,  and  this  mixture  was  incubated  at  65ºC  for 
12-14 hours, followed by treatment with RNase and 
proteinase  K.  The  DNA  was  extracted  with  phe-
nol/chloroform/isoamyl  alcohol,  precipitated,  and 
resuspended in diethylpyrocarbonate (DEPC) water. 
DNA concentrations of the samples were determined 
by Pico green fluorescence (Molecular Probes). Quan-
titative  PCR  amplification  was  used  to  amplify 
ChIP-enriched  with  DNA  using  specific  primers  to 
early origins [human beta-globin origin (hGB), human 
lamin B2 (hLB2)], primers to late origin [human am-
ylase (hA)] and primers for non-origin [human colla-
gen  (hC),  human  gamma  globulin  (hGG)].  Pair  of 
forward (F) and reverse (R) primers were the follow-
ing  for:  (i)  hBG-F-(5’-GGTGAAGGCTCATGG 
CAAGA-3’),  hBG-R-(5’-AAAGGTGCCCTTGAGGTT 
GTC-3’);  (ii)  hLB2-F-(5’-TGGGACCCTGCCCTTTTT- 
3’),  hLB2-R-(5’-CGTGACGAAGAGTCAGCT-3’);  (iii) 
hA-76-F-(5'-GATTGCCGAATATATGAACCATCTC-
3'),  hA-163-R(5'-TATGTCTCCAGGCCACATGTG-3'); 
(iv)  hC-120-F-(5'-TCTGAGAAGCCGTCCTCGTTA- 
3');  hC-200-R-(5'-CCAACAGTGGAGACACCCTT 
CTA-3');  (v)  hGG-F-(5’-GGCAAGAAGGTGCTGACT 
TCC-3’),  hGG-R-(5’-GCAAAGGTGCCCTTGAGATC- 
3’).  Probes  were  labeled  5’  with  FAM  and  3’  with 
TAMRA.  Some  experiments  were  performed  with 
VIC labeled probes with similar results. Probes were 
the  following  for:  (1)  hBG Int. J. Biol. Sci. 2011, 7 
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(5’-CCTTTAGTGATGGCCTGGCTCACCTG-3’);  (ii) 
hLB2  (5'-TTCTAGTGAGCCTCCGAC-3’);  (iii)  hA 
(5'-CATCAATTCTGAACCCTGCAACACCAATG-3'); 
(iv)  hC-3'  (5'-CGCCGCCTGGCCTGTTCCA3');  (v) 
hGG (5’-TGGGAGATGCCATAAAGCACCTGGA-3’). 
The hBG and hLB2 are located 5.2kb and 2.4kb, re-
spectively,  from  the  replication  origin,  while  hA  is 
away 104kb. For non-origin sequences the locations 
are 5.2kb for hGG and 47kb for hC. Real-time PCR and 
data analysis was performed as described previously 
[29]. Results represent three assays performed in du-
plicated. 
Identification of proteins by liquid chromatog-
raphy coupled with tandem mass spectroscopy 
(LC-MS/MS) 
HeLa  or  K562  nuclear  extracts  were  immuno-
precipitated with anti-MCP1 antibody. After, samples 
were applied in a NUPage Novex 12% gel and elec-
trophoresis  was  performed  in  a  cold  NUPage 
MOPS-SDS running buffer. The gel was stained with 
Coomassie brilliant blue (CBB). Stained protein bands 
were excised from the gel, and in-gel trypsin digestion 
was performed as previously described [30], except 
that (i) duration of destaining was extended to com-
pletely remove CBB from the diced gel pieces before 
trypsin digestion and, (ii) extracted and resuspended 
peptide  mixture  was  desalted  through  Zip-Tipm-C18 
prior to LC-MS/MS. LC-MS/MS was performed ac-
cording to the manufacturer’s specifications. Briefly, 
the  mixture  of  tryptic  peptides  was  fractionated  by 
capillary  high  performance  liquid  chromatography 
(HPLC) with flow splitter (Surveyor HPLC, Thermo 
Electron, San Jose, CA). Peptides were eluted at a flow 
rate of 250 l/min. by a gradient of 2-60% of solvent B 
(0.1% formic acid in 100% acetonitrile) in solvent A 
(0.1%  formic  acid  in  water)  and  the  eluted  peptide 
was directly sprayed into the nanospary source of a 
LTQ mass spectrometer (Thermo Electron, San Jose, 
CA).  Scans  were  acquired  in  both  MS  and  da-
ta-dependent MS/MS modes, mass range 400 to 1500 
(mass-to-charge ratios) to detect the masses of both 
parent and daughter ions. For data analysis and pro-
cessing, the Sequest algorithm was used to interpret 
MS/MS  data  [31].  The  MS/MS  data  was  searched 
against Vaccinia virus database [31]. Briefly, accepta-
ble  Sequest  results  must  have  a  Cn  score  of  0.1, 
regardless of charge state of the peptide. Acceptable 
cross-correlation score (Xcorr) must be  1.5 for a sin-
gly charged peptide and  2.0 for a peptide with a +2 
or +3 charge state. A protein that was identified by 
four or more unique peptides with Sequest scores that 
met the acceptance criteria, the protein was consid-
ered to be present in the sample analyzed.  
Antibodies 
Primary antibodies: mouse monoclonal anti-MCP1 
antibody  (mAb402)  diluted  1:3000  for  western  blot 
and  1:1000  for  immunofluorescence,  was  prepared 
and affinity immunopurified as described previously 
[25]; rat monoclonal antibody anti-BrdU (CldU), di-
luted  1:50  (OBT300,  Accurate  Chemical  &  Scientific 
Corp.).  Polyclonal  rabbit  antibodies:  anti-human 
ORC2, diluted 1:3000 (Biosciences, Pharmingen); an-
ti-human  HP1  (Upstate,  Lake  Placid,  NY),  diluted 
1:200; anti-PCNA (FL-261), diluted 1:100; anti-human 
-tubulin (H-23 h5), diluted 1:500, (Santa Cruz Bio-
technology, Inc.); anti-human MCM2, diluted 1:2000; 
anti-human Histone H3 (tri methyl K9 or MetH3K9), 
diluted 1:5000 (ab8898, AbCam); anti-human Histone 
H1, diluted 1:100 (Fl219, Santa Cruz Biotechnology, 
Inc.);  anti-human  histone  H1.2  (ab17677,  AbCam), 
diluted  1:1000;  anti-human  histone  H1.5,  diluted 
1:1000 (ab24175, AbCam). Affinity purified goat pol-
yclonal  antibodies,  diluted  1:100  (Santa  Cruz  Bio-
technology, Inc.): anti-human ORC4 (L-15), anti-Cdc6 
(C-19), anti-human Cdc45 (C-20), anti-human MCM7 
(V-17), anti-human MCM3 (G-19). Secondary antibodies: 
donkey  horseradish  peroxidase  labeled  antibodies, 
diluted  1:3000  (Santa  Cruz  Biotechnology,  Inc.):  an-
ti-goat, anti-rabbit, and anti-mouse. Affinity purified 
sheep Cy3 conjugated antibodies (Jackson Laborato-
ries), diluted 1:300: anti-mouse and anti-goat. Alexa 
Fluor488 donkey antibodies, diluted 1:200 (Molecular 
Probes): anti-rabbit, anti-mouse and anti-rat. Mouse 
IgG1 (0.5 g/ml) anti-BrdU FITC conjugated antibody 
(Becton Dickinson) for FACS. 
 
RESULTS  
Identification of MCP1 interacting proteins  
Previous  microinjection  experiments  suggested 
that MCP1 might have a role in initiating replication 
events [25]. Based on these data, it was interesting to 
inquire whether MCP1 exhibited specific associations 
with the proteins required for the establishment of the 
pre-RC.  To  assess  whether  MCP1  interacts  with 
members  of  pre-RC,  we  prepared  nuclear  proteins 
from HeLa and K562 cell lines at different phases of 
interphase.  HeLa  cells  were  synchronized  and  col-
lected at early, mid, and late S/G2 phase and the iso-
lated  proteins,  after  DNA  digestion,  were  immuno-
precipitated with anti-MCP1 antibody. In this assay, a 
mouse immunoglobulin was used as control for the 
immunoprecipitation  of  HeLa  nuclear  extracts  ob-
tained at G1/S transition.  Int. J. Biol. Sci. 2011, 7 
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Fig. 1. Immunoprecipitation (IP) of HeLa nuclear extracts 
at different phases of the cell cycle with anti-MCP1 anti-
body.  Western  blot  (WB)  of  HeLa  nuclei  from 
non-synchronized  cells  with  antibodies  used  the  detect 
MCP1 interacting proteins. (ES) - cells that were synchro-
nized at early S-phase by double thymidine block (DTB); 
(MS) - cells at middle S-phase collected 4 hours after DTB 
release; (LS/G2) - cells at late-S/G2 phase obtained 7 hours 
after DTB release. As a control, HeLa nuclear extracts at 
G1/S  transition  were  immunoprecipitated  with  a  mouse 
immunoglobulin  (mIgG).  (A)  Immunoblotting  with  an-
ti-MCP1 antibody detects the 33 kDa and 31 kDa forms of 
MCP1; (B) Proteins that interact with MCP1 were detected 
by  western  blot  with  antibodies  against  MCM2,  MCM3, 
MCM7, ORC2, Cdc6 and ORC4; (C) Cdc45 and (D) PCNA 
are co-immunoprecipitated with MCP1; (E) HP1 is not 
associated with MCP1. (F) As a loading control a Western 
blot of HeLa total cell extracts at the same cell cycle phases 
was done with anti-tubulin antibody. 
 
Immunoprecipitation with anti-MCP1 antibody 
followed  by  western  blot  with  the  same  antibody 
showed the presence of similar amounts of the 33 kDa 
and 31 kDa of MCP1 forms during the entire S-phase 
(Fig.  1A).  Western  blot  analyses  using  antibodies 
against Cdc6, ORC2, and ORC4 proteins revealed that 
these proteins co-immunoprecipitated with MCP1 at 
all stages of S-phases (Fig. 1B). Immunoprecipitation 
with anti-MCP1 antibody  followed by immunoblot-
ting  with  antibodies  against  MCM2,  MCM3,  and 
MCM7 also showed that MCP1 interacted or was as-
sociated  with  the  complex  that  contained  these 
members of MCM family (Fig. 1B). We also demon-
strated  that  Cdc45  (Fig.  1C)  and  PCNA  (Fig.  1D) 
co-immunoprecipitated with MCP1. Western blot of 
nuclear  extracts  with  anti-HP1  antibody  detected 
HP1 protein but in the extracts immunoprecipitated 
with anti-MCP1 antibody this protein was not present 
showing  that  HP1  was  not  associated  with  MCP1 
(Fig.  1E).  This  assay  confirmed  that  MCP1  did  not 
associate with proteins marking sequences that repli-
cate during late S-phase.  
In parallel, the human K562 cells, a non-adherent 
cell line, were synchronized by centrifugal elutriation 
(Fig. 2-I). This technique sorted fractions enriched at 
G1, early-S, middle-S, and late-S phases without any 
interference  due  to  the  stress  and  checkpoint  re-
sponses  induced  by  aphidicolin,  hydroxyurea,  or 
thymidine block [5]. Using isolated K562 nuclei from 
G1  and  different  S-phase  fractions,  we  have  shown 
that  MCP1  interacted  with  Cdc6,  ORC2,  ORC4, 
MCM2, MCM3, MCM7 (Fig. 2 II-B), Cdc45 (Fig. 2 II-C) 
and PCNA (Fig. 2 II-D). 
To determine whether the two forms of MCP1 
are required to interact with pre-RC proteins, we have 
performed the reciprocal immunoprecipitations with 
antibodies  against  some  members  of  the  pre-RC 
components (Cdc6, ORC2, ORC4, MCM2, MCM3, and 
MCM7),  as  well  as  Cdc45  and  PCNA. 
Co-immunoprecipitation  data  with  nuclei  prepara-
tions obtained at G1/S transition clearly showed that 
only  the  31  kDa  form  of  MCP1  was 
co-immunoprecipitated  with  Cdc6,  ORC2,  ORC4, 
MCM2,  MCM3,  MCM7,  Cdc45  and  PCNA  (Fig.  3). 
Reciprocal  immunoprecipitations  of  nuclei  with  an-
ti-HP1 and MetH3K9 antibodies followed by west-
ern blot with anti-MCP1 antibody revealed that none 
of  the  two  forms  of  MCP1  interact  with  HP1  or 
MetH3K9 (Fig. 3). Int. J. Biol. Sci. 2011, 7 
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Fig. 2. (I) Cell cycle profile of K562 cells before (A) and after elutriation at G1 (B), early-S (C), middle-S, (D), late-S (E) and 
G2 (F) phases. (II) K562 nuclear extracts synchronized by elutriation at G1, early-S (ES), middle-S (MS), and late-S (LS) were 
immunoprecipitated with anti-MCP1 antibody and detection of interacting proteins were done by western blot with an-
ti-MCP1 antibody (A), that identify the 33 kDa and 31 kDa forms of MCP1, antibodies against MCM2, MCM3, MCM7, 
ORC2, Cdc6 and ORC4 (B), Cdc45 (C) and PCNA (D), that recognize the corresponding proteins, and a mouse IgG (mIgG) 
(E) was used as a control. 
 
 
Fig. 3. Reverse co-immunoprecipitation (IP) of HeLa nuclear extracts, synchronized at early S-phase by double thymidine 
block (DBT), with antibodies against Cdc6, ORC2, ORC4, MCM2, MCM3, MCM7, Cdc45, PCNA, HP1, MetH3K9 and 
MCP1 followed by immunoblotting with anti-MCP1 antibody. The 31 kDa form of MCP1 is co-immunoprecipitated with all 
antibodies used except antibodies against HP1 and MetH3K9. Western blot (WB) immunoprecipitation (IP) with an-
ti-MCP1 antibody recognizes the 33 kDa and 31 kDa MCP1 polypeptides in HeLa nuclear extracts synchronized at early 
S-phase by DBT.  
 
HP1, which is known to co-immunoprecipitate 
with  some  ORC  proteins,  namely  in  Drosophila and 
Xenopus, associates with late replication foci [32-35]. 
We immunoprecipitated and depleted K562 nuclear 
extracts to confirm the association between ORC2 and 
MCP1, and between ORC2 and HP1. Western blot 
with  anti-MCP1  antibody  (Fig.  4A)  detected:  (i)  the 
presence MCP1 in nuclear extracts (right) and after Int. J. Biol. Sci. 2011, 7 
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immunoprecipitation with anti-MCP1 antibody (left); 
(ii) MCP1 is absente in nuclear extracts that were ini-
tially  depleted  of  MCP1  and  after  immunoprecipi-
tated with ORC2 antibody (middle). Immunoblotting 
with  anti-ORC2  antibody  (Fig.  4B)  showed:  (i)  the 
presence  ORC2  in  nuclear  extracts  (right)  and  after 
immunoprecipitation with anti-MCP1 antibody (left); 
(ii) the absence of ORC2 in nuclear extracts that were 
firstly  depleted  of  MCP1  and  after  immunoprecipi-
tated  with  ORC2  antibody  (middle).  Western  blot 
with anti-HP1 antibody (Fig. 4C) revealed that: (i) 
HP1 was present in total nuclear extracts (right) and 
in  nuclear  extracts  immunoprecipitated  with  ORC2 
antibody (left); (ii) HP1 was not present when the 
extracts  were  immunoprecipitated  with  anti-HP1 
antibody after depletion of ORC2 (middle), confirm-
ing the association between ORC2 and HP1.  
 
 
Fig. 4. (A) Western blot with anti-MCP1 antibody using 
K562 nuclear extracts that were previously immunopre-
cipitated with MCP1 (left), firstly depleted of MCP1 fol-
lowed  immunoprecipitation  with  ORC2  antibody  (mid-
dle),  and  total  nuclear  extracts  not  immunoprecipitated 
(right). (B) Western blot with anti-ORC2 antibody using 
K562 nuclear extracts that were previously immunopre-
cipitated with MCP1 (left), initially depleted of MCP1 fol-
lowed  immunoprecipitation  with  ORC2  antibody  (mid-
dle),  and  total  nuclear  extracts  not  immunoprecipitated 
(right). (C) Western blot with anti-HP1 antibody using 
K562 nuclear extracts that were previously immunopre-
cipitated with ORC2 (left), depleted of ORC2 followed 
immunoprecipitation with HP1 antibody (middle), and 
total nuclear extracts not immunoprecipitated (right). 
 
In  non-synchronized  cultures,  we  have  deter-
mined the cellular localization of MCP1 and several 
components  of  the  pre-RC  including  Cdc6,  ORC2, 
ORC4,  MCM2,  MCM3  and  MCM7,  and  Cdc45.  An 
immunofluorescence  analysis  was  also  performed 
with  the  heterochromatic  markers  HP1  and 
MetH3K9, which are known to bind ORC and associ-
ate with late replication foci [32-35]. MCP1 location is 
nuclear; it has a granular distribution throughout the 
nucleus, is not localized within the nucleolus but has a 
peripheral prominence around the nucleolus. MCP1 
and Cdc6 co-localization showed a speckled nuclear 
pattern in the nucleus of interphase MO59K cells, but 
neither  protein  was  present  at  the  nucleolus  (Fig. 
S1-A). Co-localization of MCP1 with ORC4 and ORC2 
was essentially nuclear with a peripheral accentuation 
around the nucleoli (Fig. S1-B and C). For MCP1 and 
MCM  proteins  (MCM3,  MCM7,  and  MCM2),  the 
co-localization  had  a  granular  nuclear  distribution, 
but was not detected in the nucleolus (Fig. S1-D, E and 
F). Cdc45 also exhibited speckled nuclear localization 
and  both  Cdc45  and  MCP1  showed  regions  of 
co-localization (Fig. S1-G). MCP1 did not co-localize 
with the heterochromatic proteins HP1 (Fig. S1-H) 
and MetH3K9 (Fig. S1-I). These results showed that 
MCP1  is  co-localized  with  some  of  the  proteins  re-
quired for the early events of DNA replication but not 
with proteins that mark DNA sequences replicating in 
late S-phase.  
Characterization of MCP1 by mass spectroscopy  
Characterization of 31 kDa and 33 kDa forms of 
MCP1  by  mass  spectrometry  (LC-MS/MS)  revealed 
that  this  protein  has  high  levels  of  homology  with 
histone  H1,  variants  H1.2  and  H1.5.  To  evaluate 
whether MCP1 could interact with H1 variants, his-
tone preparations and nuclear extracts from K562 cells 
were  immunoprecipitated  with  anti-MCP1  and  an-
ti-histone  H1  variant  antibodies.  Immunoprecipita-
tions  of  histone  preparations  were  performed  with 
anti-MCP1, anti-histone H1, anti-H1.2 and anti-H1.5 
antibodies followed by western blot with anti-MCP1. 
Results clearly showed the presence of two proteins 
with apparent  molecular  weights of 31 kDa and 33 
kDa  (Fig.  5A)  in  all  histone  preparations  that  were 
immunoprecipitated with antibodies against H1, H1.2 
and H1.5. In addition, the anti-MCP1 antibody did not 
recognize the 31 kDa and 33 kDa MCP1 forms when 
nuclear  extracts  were  initially  immunodepleted  of 
MCP1, H1.2 and H1.5 variants, using the respective 
antibodies  (Fig.  5B),  suggesting  the  association  be-
tween  these  proteins.  In  fact,  reverse  depletion  ex-
periments  using  anti-MCP1  antibody  showed  that 
MCP1 is associated to these two histone variants since Int. J. Biol. Sci. 2011, 7 
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both anti-H1.2 (Fig. 5-I-C) and anti-H1.5 (Fig. 5-I-D) 
antibodies did not recognize their particular antigens 
in the nuclear extracts. In the same way, immunob-
lotting  with using H1.2, H1.5 and H1 antibodies in 
total histone preparations that were immunoprecipi-
tated with MCP1 or anti-histone antibodies revealed 
the interaction between histones variants and MCP1 
(Fig. 5-IIC, II-D and E).  
 
 
Fig. 5. (A) K562 histone preparations were immunoprecipitated (IP) with anti-MCP1, histone H1 (total), histone H1.2 and 
histone H1.5 antibodies followed by western blot (WB) performed with anti-MCP1 antibody. The right lane, used as a 
control, shows the reactivity of MCP1 with anti-MCP1 antibody (B) Immunoblotting with anti-MCP1 antibody of K562 total 
nuclear extracts that were firstly depleted of MCP1, H1.2 and H1.5 using the respective antibodies. (C) (I) Western blot 
with anti-H1.2 antibody of K562 total nuclear extracts not depleted (left) and depleted (right) of MCP1; and (II) Western 
blot with anti-H1.2 antibody of total histone preparations not precipitated and previously immunoprecipitated with an-
ti-MCP1, anti-H1.2 and anti-H1.5 antibodies. (D) (I) Immunoblotting with anti-H1.5 antibody of K562 total nuclear extracts 
not depleted (left) and depleted of MCP1 (right) and (II) Western blot with anti-H1.5 antibody of total histone prepara-
tions not precipitated and previously immunoprecipitated with anti-MCP1, anti-H1.2, anti-H1.5 and anti-H1 (total) anti-
bodies. (E) Western blot with anti-H1 antibody of total histone preparations not precipitated and previously immunopre-
cipitated with anti-MCP1, anti-H1.2 and anti-H1 antibodies. 
 
MCP1 co-localizes with early replication foci  
Our  previous  data  showed  that  depletion  of 
MCP1 prevents DNA replication at early S-phase [25]. 
In  the  current  study  we  have  determined  whether 
MCP1 interacted with replication origins in early and 
late replicating loci. To address these questions, im-
munofluorescence was performed with simultaneous 
labeling of MCP1 and BrdU-substituted DNA (Fig. S2) 
in human cervix epithelial carcinoma (HeLa cells) and 
human glioblastoma (MO59K cells) to check whether 
the patterns obtained with these two cell lines were Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
201 
comparable. BrdU incorporation facilitated the iden-
tification of cells in S-phase (those cells actively in-
corporate BrdU) and the categorization of cells into 
five different stages throughout S-phase [12]. Classi-
fication of cells in S-phase relies on the observation 
that  cells  display  replication  sites  as  small  spots 
throughout the nucleus at very early S-phase (BrdU 
pattern I). Later on during early S-phase (BrdU pat-
tern  II)  replication  foci  are  larger,  discrete  and 
stronger near the nuclear boundary. During middle 
S-phase (BrdU pattern III) replication sites are located 
at the nuclear periphery and near the perinucleolar 
region.  As  cells  progress  through  S-phase,  the  late 
replication foci (BrdU pattern IV) are larger, less in 
number, and at few discrete sites at the periphery of 
the nucleus at late S-phase. Very late S-phase (BrdU 
pattern V) is characterized by the presence of smaller 
number  and  larger  areas  of  replication  sites  in  the 
interior of the nucleus and some less significant sites 
at the periphery of the nucleus [12]. In both cell lines, 
our results showed that MCP1 co-localized with BrdU 
replication  foci  at  very  early  and  early  S-phases  in 
human  cells  (Fig.  S2-A  and  B).  During  middle 
S-phase,  the  co-localization  patterns  of  MCP1  and 
BrdU were restricted to some areas around the nucle-
olus (Fig. S2-C). However, MCP1 did not co-localize 
with BrdU in cells at late stages of DNA replication 
(Fig. S2-D and E).  
We also analyzed the patterns of co-localization 
of MCP1 and PCNA, which is a marker of ongoing 
replication forks [12,14]. PCNA associates with repli-
cation  foci  at  the  onset  of  S-phase  and  co-localizes 
with the early-replicating chromatin. As cells progress 
through S-phase, PCNA is redistributed to later-firing 
compartments  of  euchromatic  replicons  and  associ-
ates  transiently  with  late  replication  domains  [14]. 
PCNA is present in the nucleus throughout the cell 
cycle  but  is  associated  with  chromatin  only  during 
S-phase [4, 12]. After labeling non-synchronized cells 
with  antibodies  against  MCP1  and  PCNA  we  ob-
served  that  MCP1  and  PCNA  co-localized  at  early 
S-phase  (Fig.  S3-A),  similarly  to  what  was  detected 
with BrdU staining. In agreement, at middle S-phase, 
MCP1 and PCNA displayed a partial co-localization 
that was restricted to a few areas around the nucleolus 
(Fig.  S3-B),  and  at  late  S-phase,  they  did  not 
co-localize  (Fig.  S3-C).  These  data  indicated  that 
MCP1  was  present  at  the early  replication  foci  and 
suggested that MCP1 might be a component of the 
pre-RC.  
Although PCNA is not a member of the pre-RC it 
is present at initiating replication forks [4, 12-14]. To 
determine whether MCP1 associated with initiating or 
elongating replication forks, we used DNA replication 
inhibitors  that  are  commonly  used  to  synchronize 
cells at G1/S transition. Aphidicolin (APH) blocks fork 
progression  but  does  not  prevent  the  initiation  of 
DNA replication and the formation of short nascent 
strands [4, 36] as it is an inhibitor of DNA polymerase 
 and  [37]. Hydroxyurea (HU) acts primarily as an 
inhibitor of ribonucleotide reductase, allows the early 
origin to be fired, but stalls the forks because of the 
lack of nucleotide precursors [36]. Thymidine (Thym) 
stops  DNA  replication  since  it  inhibits  precursor 
production  and  prevents  elongation  leading  to  the 
accumulation of cells at the very beginning of S-phase 
[36].  Immunolocalization  of  MCP1  and  PCNA  re-
vealed that MCP1 and PCNA did not show any pat-
tern of co-localization after exposure of human cells 
for 20 hours to 5 g/ml aphidicolin (Fig. S4 I-C), 2.5 
mM hydroxyurea (Fig. S4 I-D), or 2.5 mM thymidine 
(Fig. S4 I-E). A different pattern emerged when cells 
were treated with low doses of APH for shorter pe-
riods. PCNA and MCP1 did not co-localize when cells 
were treated for 1 hour with 1.0  g/ml aphidicolin 
(Fig. S4 I-B). Nevertheless, under the same conditions 
MCP1  co-localized  with  BrdU  foci  that  exhibited  a 
very  early  (Fig.  S4  II-A)  and  early  S-phase  pattern 
(Fig.  S4  II-B),  and  showed  a  few  regions  of 
co-localization at middle S-phase (Fig. S4 II-C). As in 
untreated cells (Fig. S2-C and D), MCP1 and BrdU did 
not  co-localize  according  to  the  characteristic  BrdU 
patterns of late (Fig. S4 II-D) and very late (Fig. S4 
II-E) S-stages. These data demonstrated that, unlike 
PCNA, MCP1 localized to early replication foci even 
when replication was transiently inhibited. 
MCP1 binds replication origin sequences  
The presence of MCP1 at early replication foci 
and its absence from late foci suggested that MCP1 
might bind DNA sequences that regulate DNA repli-
cation.  To  evaluate  this  hypothesis,  we  performed 
chromatin-immunoprecipitation  (ChIP)  using  DNA 
sequences that are located at various distances from 
known replication origins. For this assay we used a 
human  erythroleukaemia  cell  line  K562  because  in 
these  cells  the  human  beta-globin  gene  locus  repli-
cates early in S-phase [38] whereas amylase and col-
lagen  replicated  late  [39,  40].  The  human  lamin  B2 
locus  also  replicates  early  in  those  erythroid  cells. 
Probes used included two genes from the beta-globin 
locus  (beta-globin  is  origin  proximal  and  gam-
ma-globin is distal), the origin-proximal region of the 
human lamin B2 locus and the late origin human am-
ylase  locus.  Quantitative  analysis 
MCP1-immunoprecipitated  chromatin  (Fig.  6)  re-
vealed enrichment over the input of 3.2-fold for hu-
man lamin B2 and 4.3-fold for beta-globin sequences. Int. J. Biol. Sci. 2011, 7 
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The  gamma-globin  and  collagen  regions  show  little 
enrichment (0.9 to 1.4-fold), and late origin sequences 
for  amylase  locus  were  depleted.  As  primers  were 
selected according to locations known either as initia-
tion or non-initiation regions as positive and negative 
markers for origin and non-origins sites, these data 
suggest that MCP1 binds  preferentially to the early 
origins sequences.  
 
 
Fig. 6. Chromatin immunoprecipitation (ChIP) from K562 
cells using anti-MCP1 antibody followed by real time PCR 
analysis of the abundance of specific DNA sequences in 
MCP1-bound chromatin. Probes included the human be-
ta-globin (hBG), human lamin B2 (hLB2), human amylase 
(hA), human gamma-globin (hGG) and human collagen (hC). 
The human lamin B2 and beta-globin loci replicate early in 
K562 cells, and the human amylase replicate late. The hu-
man gamma-globulin and human collagen were used for a 
non-origin control. 
 
DISCUSSION  
Despite  the  recent  advances  in  understanding 
the processes of initiation and of DNA replication, the 
specific mechanisms that determine the assembly of 
the components of the pre-RC and those that regulate 
the chromatin structure remain to be elucidated.  
The present work aimed to determine whether 
MCP1 interacts with several proteins required for the 
initiation of DNA replication. This was evaluated by 
immunoprecipitation in cells that were synchronized 
at G1 and at different S-phases, using drug treatment 
or  elutriation.  By  reverse  co-immunoprecipitation 
assay, we showed that the interactions between MCP1 
and several proteins of the pre-RC, Cdc45 and PCNA 
were  done  through  the  31  kDa  form.  Importantly, 
MCP1 did not interact with heterochromatin proteins 
like HP1, a key component of condensed DNA that 
also binds ORC [32] and is strongly implicated in gene 
silencing and centromeric cohesion [34]. It also did not 
interact  with  MetH3K9,  which  is  implicated  in 
HP1-nucleosome  interaction  and  genomic  stability 
[33].  Moreover,  immunofluorescence  revealed  the 
presence of patterns of co-localization between MCP1 
and  proteins  that  were  co-immunoprecipitated,  but 
not with those that did not interact with MCP1. 
Data from ChIP analysis suggested a preferential 
association of MCP1 with origins that replicate early 
in  S-phase  or  sequences  that  replicate  early  when 
compared with late origin and sequences that repli-
cate in late S-phase. In metazoans, sequences associ-
ated  to  early  and  late  replication  foci  are  not  well 
characterized, but there are several DNA sequences 
confined to initiation that requires the cooperation or 
can be affected by other distal sequences, gene tran-
scription and epigenetic modifications [1, 2]. Accord-
ingly, we also detected the presence of MCP1 at ear-
ly-replicating  loci,  as  shown  by  the  co-localization 
patterns  displayed  by  MCP1/BrdU  and 
MCP1/PCNA. Early foci can be detected in the de-
condensed euchromatin region, as hundreds of small 
replication foci, each with 5-6 replicons. Late loci are 
larger  replication  factories,  containing  clusters  of 
hundreds of replicons that could be visualized in the 
condensed heterochromatic region in late S-phase [2, 
12]. These findings are in conformity with the previ-
ous microinjection experiments that demonstrated the 
requirement  of  MCP1  for  the  G1/S  transition  and 
early S-phase [25]. In contrast to PCNA, MCP1 was 
also detected at early replication foci, after short pe-
riod and low concentration of drugs that inhibit the 
progression  of  replication  forks.  Displacement  of 
PCNA from replications forks, after exposure to low 
doses of APH had been previously shown [41] and 
allow  the  repair  of  transient  breaks  [42].  Because 
MCP1  interacted  with  ORC  proteins,  but  not  with 
HP1, and as some ORC members are also partners of 
HP1, as previously determined [32, 35, 43] and also 
supported by data of this work, we cannot rule out 
that  ORC  forms  different  complexes  with  various 
proteins.  Here,  depletion  experiments  performed  in 
K562  cells,  followed  immunoprecipitation  and  im-
munoblotting,  indicated  that  ORC2  can  bind  HP1 
and  ORC2  can  bind  MCP1.  Moreover,  immunopre-
cipitation and reverse co-immunoprecipitation assays, 
using nuclear extracts from HeLa cells, also confirmed 
the  interaction  between  MCP1  and  ORC2,  and  the 
lack of association between MCP1 and HP1. In that 
way, when ORC2 was depleted from the extracts we 
were not able to detected HP1, but this does not im-
ply that all ORC2 was bound to HP1. So, there could 
be two sub-fractions of ORC2, one bound to MCP1 Int. J. Biol. Sci. 2011, 7 
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and  another  bound  to  HP1.  Probably  those  com-
plexes form at different times during the cell cycle or 
are dependent of different types of chromatin archi-
tecture or environment. These facts might imply that 
ORC2 interacts with MCP1 on early origins and with 
HP1  on  late  origins.  The  functional  importance  of 
such complex switching and its possible role  in de-
termining replication timing can be implied and ex-
plored in later studies. 
In spite of MCP1 being present mainly at early 
replicating  foci,  we  showed  that  these  interactions 
with the pre-RC components are maintained during 
S-phase and also at G1 to G2 phases. MCP1 levels are 
stable throughout the G1, S and G2 phases, and the 
protein-protein  interaction  seems  to  be  constant 
throughout interphase. These observations were not 
in a chromatin bound context, which is variable for 
Cdc6, MCM Cdc45 or PCNA [5, 11, 44, 45]. In fact, the 
expression and localization of these proteins change 
during S-phase, respectively for ORC2-6 [1, 6, 46] and 
PCNA [4, 12, 45], but the interaction described here 
occurs  between  proteins  obtained  from  nuclear  ex-
tracts after DNA digestion. Thus, it is possible that 
MCP1 interacts with pre-RC components that are lo-
cated  on  early-replicating  loci  poised  to  start  DNA 
replication. This hypothesis is consistent with earlier 
observations that MCP1 sequestering causes the inhi-
bition of S-phase progress [25]. An additional role for 
MCP1 might be to participate in structural chromatin 
changes that are required not only for DNA replica-
tion  but  also  for  other  important  cellular  functions. 
This suggestion is supported by our observation that 
MCP1  interacts  with  histone  H1  and  its  variants. 
However,  unlike  histone  depletions,  in  which  func-
tion  of  a  missing  variant  may  be  compensated  by 
other members of the H1 family or additional proteins 
of the chromatin [15], the lack of MCP1 prevents DNA 
replication  [25].  Recently,  the  presence  of  H1.2  and 
H1.5 was shown at DNA replication and transcription 
sites [47]. 
The nuclear localization of MCP1 [24] suggests 
that MCP1 might be a structural component of chro-
matin and it might attach some proteins of replication 
factory  or  might  participate  in  complexes  that  con-
tribute to chromatin remodeling that is required for 
replication,  transcription  or  repair.  In  the  present 
work we only analyzed the interactions of MCP1 with 
several components associated to replication machin-
ery  and  histones,  but  a  proteomic  approach  would 
allow the characterization the other MCP1 partners, as 
described for PCNA [45]. We cannot rule out other 
functions for MCP1, since it was identified with an 
antibody from mice with SLE [21], and might be im-
plicated in other relevant cellular events similarly to 
others proteins recognized by autoimmune sera, like 
Ku  or  PCNA  [22,  23,  45,  48,  49].  The  molecular 
mechanisms underlying the proposed models will be 
the subject of our future investigation. 
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Fig.  S1.  Co-localization  patterns,  in  non-synchro-
nized cultures, in human MO59K cells of MCP1 (red) 
and Cdc6 (A), ORC4 (B), ORC2 (C), MCM3 (D), 
MCM7 (E), MCM2 (F), Cdc45 (G), HP1 (H), and 
MetH3K9 (I) proteins (green). See text for details. 
Barr = 10c. 
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Fig. S2. Immunolocalization of MCP1 (red) and BrdU (green) in human MO59K cells. Classification of cells in S-phase relies 
on the observation that cells display replication sites as small spots throughout the nucleus (A) at very early S-phase (BrdU 
pattern I). Later on during early S-phase (BrdU pattern II) replication foci are larger, discrete and stronger near the nuclear 
boundary (B). During middle S-phase (BrdU pattern III) replication sites are located at the nuclear periphery and near the 
perinucleolar region (C). As cells progress through S-phase, the late replication foci (BrdU pattern IV) are larger, less in 
number, and at few discrete sites at the periphery of the nucleus at late S-phase (D). Very late S-phase (BrdU pattern V) is 
characterized by the presence of smaller number and larger areas of replication sites in the interior of the nucleus and some 
less significant sites at the periphery of the nucleus (E). Barr = 10c. Int. J. Biol. Sci. 2011, 7 
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Fig. S3. Immunolocalization of MCP1 (red) and PCNA (green) in non-synchronized human MO59K cells. MCP1 associates 
with PCNA at early S-phase (A) replicating foci. In middle S-phase (B) MCP1 partially co-localizes with PCNA. At late 
S-phase (C), MCP1 does not co-localize with PCNA. Barr = 10c. 
 
Fig. S4. (I) Immunolocalization, of MCP1 (red) and PCNA (green) in human MO59K control cells shows that both proteins 
co-localize at early S-phase (A). MCP1 and PCNA do not co-localize after treatment with 1 g/ml aphidicolin (APH) for 1 Int. J. Biol. Sci. 2011, 7 
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hour (B), or after 20 hours of incubation with 5 g/ml aphidicolin (C), 2.5 mM hydroxyurea (HU) (D), or 2.5 mM thymidine 
(Thym) (E). (II) Immunolocalization patterns of MCP1 (red) and BrdU (green) in human MO59K cells after treatment with 
1 g/ml aphidicolin for 1 hour. MCP1 associates with BrdU replicating foci at very early (A) and early S-phases (B), at middle 
S-phase MCP1 partially co-localizes with BrdU (C), and at late (D) and very late S-phases, MCP1 and BrdU do not co-localize 
(E). Barr = 10c. 